Molecular subtyping and target identification in triple negative breast cancer through immunohistochemistry biomarkers
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Immunohistochemistry (IHC) effectively subtypes Triple-Negative Breast Cancer (TNBC), identifying distinct molecular profiles. These subtypes significantly impact patient prognosis and survival, highlighting IHC
Area Of Science
- Oncology
- Molecular Biology
- Pathology
Background
- Triple-Negative Breast Cancer (TNBC) molecular subtyping is crucial for treatment but lacks extensive data.
- Immunohistochemistry (IHC) offers a valuable tool for TNBC subtyping and target identification in routine clinical practice.
Purpose Of The Study
- To assess the utility of IHC for subtyping TNBC and identifying prognostic biomarkers.
- To investigate the correlation between IHC-defined TNBC subtypes and patient survival outcomes.
Main Methods
- IHC expression of subtyping and predictive biomarkers was analyzed in a TNBC cohort.
- Clinicopathologic parameters and overall survival (OS) were evaluated in relation to IHC subtypes.
Main Results
- Five main IHC subtypes were identified: Basal-like1 (BL1), Basal-like2 (BL2), Mesenchymal (MES), Luminal Androgen Receptor (LAR), and Mixed.
- Significant differences in median overall survival (OS) were observed among the subtypes, with LAR showing the longest OS.
- TNM staging and TNBC subtypes independently influenced OS, underscoring their prognostic value.
Conclusions
- IHC is a valuable method for TNBC subtyping and prognostic assessment.
- IHC-based subtyping can aid in identifying therapeutic targets and improving patient care.
- Further research is needed to validate these findings and establish IHC as a routine diagnostic tool for TNBC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
